176655-57-5

Basic information

• Product Name: Des(isopropylthiazolyl) Ritonavir
• Synonyms: Des(isopropylthiazolyl) Ritonavir;(3S,4S,6S,9S)-
• CAS NO: 176655-57-5
• Molecular Formula: C30H39N5O5S
• Molecular Weight: 581.72616
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Sulfur & Selenium Compounds;Chiral Reagents, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 176655-57-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Des(isopropylthiazolyl) Ritonavir(CAS DataBase Reference)
• NIST Chemistry Reference: Des(isopropylthiazolyl) Ritonavir(176655-57-5)
• EPA Substance Registry System: Des(isopropylthiazolyl) Ritonavir(176655-57-5)

Safety Data

• Hazardous Substances Data: 176655-57-5(Hazardous Substances Data)

Usage

Description

Des(isopropylthiazolyl) Ritonavir, also known as R535000, is a metabolite of Ritonavir, an orally active HIV-1 protease inhibitor. It is derived from the parent drug through metabolic processes in the body and has been found to possess potential therapeutic properties.

Uses

Used in Pharmaceutical Industry:
Des(isopropylthiazolyl) Ritonavir is used as an active pharmaceutical ingredient for the treatment of HIV-1 infection. As a metabolite of Ritonavir, it contributes to the overall therapeutic effect of the parent drug by inhibiting the replication of the virus in the body.
Used in COVID-19 Research:
Des(isopropylthiazolyl) Ritonavir is used as a research compound in the context of COVID-19. Its potential application in the development of treatments or therapies for the disease is being explored, leveraging its background as a metabolite of an HIV-1 protease inhibitor.

Upstream product

• 155213-67-5 ritonavir 

Relevant articles and documents

Recombinant expression and characterization of novel P450s from Actinosynnema mirum

Cytochrome P450 monooxygenases (P450s) are the major contributor in the metabolism of xenobiotics, including therapeutic agents. Thus, P450s find broad application in the pharmaceutical industry to synthesize metabolites of new active pharmaceutical ingredients in order to evaluate toxicity and pharmacokinetics. As an alternative to human hepatic P450s, microbial P450s offer several advantages, such as an easier and more efficient heterologous expression as well as higher stability under process conditions. Recently, the wild-type strain Actinosynnema mirum has been reported to catalyze hydroxylation reactions with high activity on a broad range of substrates. In this study, one of these substrates, ritonavir, was used to analyze the transcriptional response of the wild-type strain. Analysis of the differential gene expression pattern allowed the assignment of genes potentially responsible for ritonavir conversion. Heterologous expression of these candidates and activity testing led to the identification of a novel P450 that efficiently converts ritonavir resembling the activity of the human CYP3A4.